Pain & Sensory Evaluation System

medoc

PATHWAY

ATS / CHEPS





- New Capabilities in advsnced thermal stimulation
- New Directions in investigating various acute & chronic pain conditions
- New Possibilities towards defining underlying mechanisms in pain processing

...towards objective evaluation of small nerve-fiber function A Configuable and Expandable Advanced Thermal Stimulator for today's & tomorrow's research protocols, pharmacologic investigations and clinical applications.



PATHWAY Pain & Sensory Evaluation System

An advanced thermal stimulator offering new possibilities in the investigation of human nociceptive pathways



Contact-Heat Evoked Potential Stimulation (CHEPS)

PATHWAY enables pain and nonpainful evoked potential recording of both Adelta & C fiber function: allowing for the first time, selective activation & objective identification of nerve fiber activity through EEG recording. Extremely fast heating (70'c / sec) and temperature sampling (200 times/ sec) delivers thermal stimuli with precise temperature and pattern control.





Temporal Summation Superior temperature control

capabilities for rapid and programmable delivery of sensory stimuli at a windup frequency (<0.33 Hz) to induce temporal summation. Windup is an important modality for functional evaluation of central pain processing mechanisms related to central sensitization.



Advanced Thermal Stimulator (ATS)

ATS enables QST (Quantitative Sensory Testing) via delivery of painful and non-painful thermal stimuli. ATS thermal stimulation can range from 0'C to 55'C, thus opening new research horizons for deep cold pain & heat pain studies.

fMRI

PATHWAY is available in an fMRI conditional* configuration in both ATS and CHEPS models. Rapid CHEPS stimulation can provide synchronized and fMRI compatible EEG recording of A-delta & C-fiber electrophysiology.

*See detailed information in the PATHWAY Operation Manual

Pharmaceutical Clinical Trials

PATHWAY induced CHEPS can potentially be used as a new 'surrogate marker' assisting in prioritization of new & existing compounds, reduction of statistical sample, dosage definitions - all resulting in shortening time to market.

DC 00035 REV-7



Medoc Ltd. 1 Ha'Dekel St. Ramat Yishai, Israel 30095 +972-4-903.8800 | info@medoc-web.com

www.medoc-web.com

